EUCTR2009-017011-16-SE进行中(未招募)不适用
Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study
niversity Federico II0 个研究点开始时间: 2011年5月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients of either sex affected by CHF NYHA class II-III, secondary to ischemic or idiopathic dilated cardiomyopathy
- •Age range 30-80 years
- •Stable medications for at least two months prior to randomization, including ACE inhibitors or AT1 antagonists and beta-blockers (unless untolerated).
- •LV ejection fraction 40% or less
- •Peak VO2 consumption during a CPET = 16 ml/kg/min.
- •LV end-diastolic dimension 55 mm or more
- •Low IGF-1 levels and a satisfactory response to an IGF-1 generation test (see below)
- •Positive result after GH-provocation test (PD-GHRH; cut-off GH levels defined as 18.3, 9.0, and 5.0 mg/l for normal weight, overweight and obese subjects respectively)
- •Informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 84
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 84
排除标准
- •Haemodynamic clinically significant primary valvular disease or significant congenital heart disease
- •Acute pericarditis/myocarditis
- •Inability to perform a bicycle exercise test
- •Poorly controlled diabetes mellitus (HbA1c >8.5)
- •Active proliferative or severe non-proliferative diabetic retinopathy
- •Active and/or history of malignancy
- •Evidence of progression or recurrence of an underlying intracranial tumor
- •Unstable angina or recent myocardial infarction (less than 5 months)
- •Severe liver disease
- •Serum creatinine levels >2.5 mg/dl
- •Inability to cooperate or administer the study drug
- •Patients participating in any other clinical study, within 30 days prior to screening visit and/or during this particular study period
- •With regard to inclusion criterion no. 7, an IGF-1 level will be considered low if below the 25th percentile of a sex and age matched population (33-35). The following cut-off values will be used: 130 ng/ml (age 30-39 y); 115 ng/ml (age 40-49 y); 105 ng/ml (age 50-59 y); 95 ng/ml (age 60-69 y); 85 ng/ml (age 70-80 y).
研究者
相似试验
暂停
2 期
Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.Chronic Heart FailureNCT01235273Federico II University100
尚未招募
Unknown
In this study healthy children and adolescents of 5-16 years are group are taken to determine chronological age bone age and correlate them with serum IGF-1 levels.CTRI/2024/05/067782Jawaharlal Nehru Medical College, KLE University, Belagavi
未知
Unknown
Administration study for IGF-1 and somatropin to healthy Japanese adult femalesJPRN-jRCT1080221643Mitsubishi Chemical Medience Corporation8
已完成
不适用
Efficiency of insulin-like growth factor 1 therapy for cerebral ischemia by cardiopulmonary arrestJPRN-UMIN000018553Emergency and critical care center30
已完成
2 期
Pioglitazone in the treatment of acromegalyMetabolic and Endocrine - Metabolic disordersAcromegalyACTRN12610000780055Auckland district health board20
